These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2295792)

  • 21. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.
    DeFrees S; Wang ZG; Xing R; Scott AE; Wang J; Zopf D; Gouty DL; Sjoberg ER; Panneerselvam K; Brinkman-Van der Linden EC; Bayer RJ; Tarp MA; Clausen H
    Glycobiology; 2006 Sep; 16(9):833-43. PubMed ID: 16717104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
    Albrecht H; Denardo GL; Denardo SJ
    J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
    Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors.
    Mattijssen V; Balemans LT; Steerenberg PA; De Mulder PH
    Int J Cancer; 1992 Jul; 51(5):812-7. PubMed ID: 1612787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [In vivo antitumor activities of polyethylene glycol modified recombinant interleukin 2 (PEG-rIL-2) against murine hepatoma].
    Feng XS
    Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):256-8. PubMed ID: 8174461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The uses and properties of PEG-linked proteins.
    Delgado C; Francis GE; Fisher D
    Crit Rev Ther Drug Carrier Syst; 1992; 9(3-4):249-304. PubMed ID: 1458545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyethylene glycol conjugation of recombinant methioninase for cancer therapy.
    Tan Y; Sun X; Xu M; An Z; Tan X; Han Q; Miljkovic DA; Yang M; Hoffman RM
    Protein Expr Purif; 1998 Feb; 12(1):45-52. PubMed ID: 9473456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEGylation of interleukin-6 effectively increases its thrombopoietic potency.
    Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Kaneda Y; Ohsugi Y; Mayumi T
    Thromb Haemost; 1997 Jan; 77(1):168-73. PubMed ID: 9031469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan.
    Sheng Y; Liu C; Yuan Y; Tao X; Yang F; Shan X; Zhou H; Xu F
    Biomaterials; 2009 Apr; 30(12):2340-8. PubMed ID: 19150737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Final report on the safety assessment of Triethylene Glycol and PEG-4.
    Int J Toxicol; 2006; 25 Suppl 2():121-38. PubMed ID: 17090481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication.
    Kronman C; Cohen O; Raveh L; Mazor O; Ordentlich A; Shafferman A
    Toxicology; 2007 Apr; 233(1-3):40-6. PubMed ID: 17045722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.
    Knauf MJ; Bell DP; Hirtzer P; Luo ZP; Young JD; Katre NV
    J Biol Chem; 1988 Oct; 263(29):15064-70. PubMed ID: 3049599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.
    Takagi A; Yamashita N; Yoshioka T; Takaishi Y; Sano K; Yamaguchi H; Maeda A; Saito K; Takakura Y; Hashida M
    J Control Release; 2007 Jun; 119(3):271-8. PubMed ID: 17490774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins.
    Richter AW; Akerblom E
    Int Arch Allergy Appl Immunol; 1983; 70(2):124-31. PubMed ID: 6401699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mannosamine-biotin as a novel masking agent for coating IgG for immune response silencing and augmentation of antibody-antigen interaction.
    Vaya J; Aizenshtein E; Khatib S; Gefen T; Fassler M; Musa R; Krispel S; Pitcovski J
    Vaccine; 2009 Nov; 27(49):6869-76. PubMed ID: 19765399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-2: use in solid tumors.
    Bukowski RM; McLain D; Olencki T; Budd GT; Murthy SA
    Stem Cells; 1993 Jan; 11(1):26-32. PubMed ID: 8457777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refolding and proton pumping activity of a polyethylene glycol-bacteriorhodopsin water-soluble conjugate.
    Sirokmán G; Fasman GD
    Protein Sci; 1993 Jul; 2(7):1161-70. PubMed ID: 8358299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.